AAM Steps Into GSK-Teva Case To Defend Carve-Outs
Ruling On Skinny Labels Must Not Become ‘Road Map’ For Originators
Executive Summary
The AAM has stepped into controversial litigation between Teva and GSK over generic labelling carve-outs, urging the US Court of Appeals for the Federal Circuit to rehear the case to prevent the rules on so-called skinny labels from being subverted.
You may also be interested in...
Generic ‘Skinny Labels’ Get Reprieve As Court Agrees To Rehear Teva/GSK Case
Federal Circuit panel to reconsider whether Teva induced infringement of GSK Coreg patent despite label carve-out. Biologics and biosimilars could be particularly hurt if ruling stands given FDA’s recent guidance requiring reference to branded product.
US Court Offers Second Chance On GSK-Teva ‘Skinny Label’ Ruling
A controversial ruling that threatens so-called “skinny label” carve-outs of patented indications by US generics will be re-examined by the Court of Appeals for the Federal Circuit, following a petition by Teva.
Latest Vascepa Lawsuit Plunges Hikma Into Induced Infringement Battle
Hikma has pushed back against a further attempt by Amarin to counter its US generic version of Vascepa, this time via a fresh lawsuit claiming that the generic induces infringement of patents protecting cardiovascular indications for which the brand is approved but which are carved out of the generic label.